Does Cymbalta Affect Sex Drive? What the Duloxetine and Effexor Studies Show

Cymbalta and sex drive: in a pooled analysis of four trials, 46.4% of people on duloxetine developed a sexual problem during treatment. That was significantly more than placebo, and lower than paroxetine's 61.4% in the same pool. Effexor (venlafaxine) shows up higher on the lists: 67.3% in one study of 1,022 outpatients, and second of ten antidepressants in a meta-analysis ranking. Both drugs measurably flatten desire for a large share of people, and venlafaxine does more of it than duloxetine. The condition underneath, whether depression, anxiety or pain, does part of the work too.

Figures from Nelson et al. 2006 (PMID 16964316), Montejo et al. 2001 (PMID 11229449) and Serretti and Chiesa 2009 (PMID 19440080).

Is it the Cymbalta, or is it me?

If you type "Cymbalta and sex drive" into a search bar, you want a verdict. You are reading this page because your wanting went quiet, and you are trying to work out whether the medication is the reason or whether the diagnosis is. Here is the honest answer: both, usually. You are on one of two drugs in the same family, the SNRIs, serotonin and noradrenaline reuptake inhibitors. They lift mood and steady nerves, and they nudge the same chemistry that your desire runs on.

The class behind both drugs carries this risk. You can read more in our guide to SSRIs and libido, in our page on antidepressants and low libido, and in our guide to depression and low libido. The condition itself drags desire down, whether the diagnosis is depression, anxiety or pain, and the drug adds on top. The sections below walk the evidence for each drug, and the part of the picture that comes from pain.

What the duloxetine trials found

Nelson and colleagues (2006) pooled four clinical trials: 1,466 people in total, 736 on duloxetine, 359 on paroxetine, 371 on placebo. Paroxetine is an SSRI, an older antidepressant from a neighbouring class, which is why it is in this pool alongside duloxetine. Treatment-emergent sexual problems were significantly more common on duloxetine than on placebo (p = .007), and even more common on paroxetine (p below .001).

But duloxetine was also significantly lower than paroxetine: 46.4% versus 61.4% (p = .015). The honest read is that four in ten people on duloxetine picked up a new sexual problem, and that the drug is meaningfully milder than paroxetine on this measure.

The rest of the pool is useful context. People stopped the treatment for side effects at similar rates, duloxetine 8.0% versus paroxetine 6.1%, and the difference was not significant. Blood pressure changes were modest and did not differ between the groups. One important gap: the abstract does not give the placebo rate of sexual problems, so you cannot see exactly how far duloxetine sat above it. The direction is printed, and so is the gap between the two active drugs. That is what the chart shows.

Effexor, near the top of every list

Effexor (venlafaxine) does not sit where duloxetine sits. Montejo and colleagues (2001) ran a prospective multicentre study of 1,022 outpatients, 610 women and 412 men with a mean age of 39.8, all with previously normal sexual function, interviewed with a questionnaire. Overall, 59.1% (604 of 1,022) scored in the dysfunction range. By drug, venlafaxine came in at 67.3% (37 of 55), third of the drugs in that study, behind citalopram at 72.7% and paroxetine at 70.7%, and ahead of sertraline at 62.9% and fluoxetine at 57.7%.

The 55-person venlafaxine arm means the direction is clear and the exact number is less precise. Men scored 62.4% and women 56.9%, with women reporting higher severity, and about 40% of the group showed low tolerance to the effects. Duloxetine was not on the market during this study.

Serretti and Chiesa (2009) meta-analysed the trials that asked directly about treatment-emergent problems, and ranked the drugs that came out significantly above placebo. The list of ten, in decreasing order of impact: sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram, fluvoxamine. Venlafaxine is second; duloxetine is eighth. Clayton and colleagues (2002) looked at 4,534 women and 1,763 men across 1,101 US primary-care clinics. SSRIs, mirtazapine and venlafaxine XR sat in a 36% to 43% band. In a subgroup without other risk factors, the odds were 4 to 6 times greater on SSRIs or venlafaxine XR than on bupropion SR, and the physicians in that study consistently underestimated how often these problems occurred. Where bupropion appears, you can compare the two in our Wellbutrin page.

Where the two SNRIs sit in the class

In the Serretti and Chiesa (2009) ranking of ten antidepressants significantly above placebo, venlafaxine is second and duloxetine is eighth. The same review found no significant difference from placebo for bupropion, mirtazapine and nefazodone. The ordering inside the list of ten is the part to hold loosely: per-drug percentages were not given in the abstract, and the ranking is by size of effect among the drugs that cleared the significance bar, with rates running from 25.8% to 80.3% across the group. Both SNRIs clear that bar in every review that includes them.

A later network meta-analysis, Reichenpfader and colleagues (2014), pulled together 63 studies, 58 of them randomized and five observational, covering more than 26,000 people on second-generation antidepressants. Most head-to-head comparisons looked similar, the credible intervals were wide, and the overall strength of evidence was rated low. The authors said the results do not allow a precise estimate of comparative risk. Duloxetine and venlafaxine are not singled out in that abstract.

Kearns and colleagues (2022) ran a Bayesian network meta-analysis of placebo-controlled trials of eight antidepressants, duloxetine and venlafaxine among them, and found that all eight were associated with increased rates of sexual problems relative to placebo. The reviews agree on the direction and disagree on the exact order. No randomized trial has compared switching between these drugs, so a duloxetine-versus-Effexor verdict on this measure is not settled by evidence.

Cymbalta for pain: the other reason you are on it

A lot of people take Cymbalta for fibromyalgia or nerve pain, and some take it for depression or anxiety. The pain angle changes the picture in a way most drug-versus-drug comparisons miss. The pain itself is a desire lever. Chronic pain, the tired all the time that comes with it, and the strain on a relationship all pull wanting down on their own, before you add a single pill. If your numbers on a lab sheet look fine and you still feel flat, that is a real pattern, and our guide to normal numbers and low libido covers it. There is also a guide to chronic pain and low sex drive if that fits your story.

So what does the pain drug actually do for the pain? Welsch and colleagues (2018) reviewed the SNRIs for fibromyalgia in a Cochrane review: 18 studies, 7,903 people, seven of them on duloxetine and nine on milnacipran. Just under a third of the people on duloxetine or milnacipran got pain relief of 50% or more: 31% (1,274 of 4,104) versus 21% (591 of 2,814) on placebo, a risk difference of 0.09 (95% CI 0.07 to 0.11), a number needed to treat of 11. The authors reported "no clinically relevant benefit" on that outcome.

On patients' global impression of improvement the gap was bigger: 52% (888 of 1,710) versus placebo, a risk difference of 0.19 (95% CI 0.12 to 0.26), number needed to treat 5. The quality of the evidence was low, and very low for serious adverse events. That review does not report sexual side effects, so no figure comes from it. The takeaway: the pain benefit is modest, and the pain itself is likely doing real work on your desire, on top of the drug.

The two SNRIs, review by review

Six looks at the two drugs, in date order, each with its caveats, so the whole picture stays visible.

Drug by drug: the share who reported a sexual problem in one 1,022-person study, and where each drug sits in a ten-drug ranking

Drug	Reported a sexual problem (Montejo 2001)	Rank of ten (Serretti 2009)	Note
citalopram	72.7%	third	SSRI
paroxetine	70.7%	fourth	SSRI, also 61.4% in the duloxetine trials
Effexor (venlafaxine)	67.3%	second	SNRI
sertraline	62.9%	first	SSRI
fluvoxamine	62.3%	tenth	SSRI
fluoxetine	57.7%	fifth	SSRI
Cymbalta (duloxetine)	not studied in 2001; 46.4% in four pooled trials	eighth	SNRI
mirtazapine	24.4%	no significant difference from placebo	not an SNRI
nefazodone	8%	no significant difference from placebo	no longer sold

What actually helps, graded honestly

The options that have been tested in trials, in order of the evidence. First, adding bupropion to the current antidepressant. Taylor and colleagues (2013) reviewed 23 trials covering 1,886 people. Bupropion at 150 milligrams twice daily beat placebo (SMD 1.60, 95% CI 1.40 to 1.81, three studies, men and women), while 150 milligrams once daily did not (RR 0.62, 95% CI 0.09 to 4.41). de Aquino and colleagues (2025) reviewed 11 trials in 859 women and found the same dose improved desire (1.74, 95% CI 1.03 to 2.44), with the quality of evidence graded low. What the bupropion trials show covers that line of work.

Second, erection drugs for men. Sildenafil, tested in three studies covering 255 men, and tadalafil, in one study covering 54 men, improved erection scores. For women, the evidence on sildenafil is uncertain. Luft and colleagues (2021) reviewed 57 citations, 33 interventions and 3,108 patients. 44% of trials reported success, with 70% of open-label studies versus 22% of placebo-controlled studies, and sildenafil was the most consistent signal. Open-label results flatter an effect, so read that gap as a caveat.

Third, everything else failed or has not been properly tested. The Cochrane review found the other augmentation strategies did not demonstrate significant improvements, and there are no randomized trials of switching drugs, of drug holidays, or of psychological approaches. Libido after stopping antidepressants looks at the stopping question.

Does it wear off on its own?

The best data on this question comes from an SSRI study, so read it as a pointer, since duloxetine and venlafaxine are SNRIs. Landen and colleagues (2005) followed people with stubborn depression on citalopram or paroxetine. When asked directly, 41% reported a sexual problem, against 6% who volunteered it unprompted (p below .001). The rate tracked the length of the depressive episode and did not track age, dose, blood level, treatment length or depression scores, and the authors concluded these side effects do not abate over time.

Two things to keep in mind. First, that study measured what happens while a person stays on the drug. It did not measure what happens after stopping. Second, do not stop or change the dose on your own.

What to bring to your prescriber

A short, prepared conversation makes the options real. Bring these six things:

1. Which condition the drug is for. The levers differ for pain and for mood, since a pain patient's flatness may be as much the pain as the drug, and the same holds for anxiety.
2. The timeline. When the medication started, when the flatness began, and whether the two line up, in plain dates.
3. Ask to be asked. In one study 41% reported a sexual problem when asked directly, but only 6% volunteered it, so say it out loud before you sit down.
4. That dose is not the lever. The same study found the rate did not track dose, so a dose change is a decision for your prescriber, and on its own it will not fix the flatness.
5. The three options with their evidence. Wait and watch, add bupropion, or switch drugs. Each has the limits noted above, and switching has no randomized trial behind it yet.
6. The supplement question, bottle in hand. If you want to try a botanical, bring the actual product so your prescriber can read the label and make the call.

The everyday levers, and where a botanical fits

Start with who this section is not for. Blood-pressure medication and heart, kidney and lung conditions are exactly what a prescriber watches on these drugs, and they are what the label warns about: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. For some readers of this article, that sentence is the answer. Talk to your prescriber first and bring the label.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits.

• Sleep, in quantity and quality, since fatigue from depression, anxiety or pain feeds broken sleep, and broken sleep feeds flatness. Sleep, libido and testosterone covers that loop.
• Movement you can sustain with pain, small and regular, since pain and inactivity pull in the same direction. Exercise and libido covers the wider picture.
• Care for the mood or the pain as the first lever, since the condition under the medication does part of the flattening too.
• Time with a partner or on your own, with nothing expected at the end.
• A botanical supplement, if you want one, as the smallest lever on the list.

NUUD is a botanical supplement built around desire in general. It does nothing for depression, anxiety, pain, or the side effects of duloxetine, venlafaxine or any antidepressant, and it has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your prescriber decides the rest. If your prescriber has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

If your first thought was "Is it the Cymbalta, or is it me?", hold that question for a second, because the honest answer is usually both, plus your life. The numbers, in plain words: in the four pooled trials, 46 out of every 100 people on Cymbalta reported a sexual problem, and in the 1,022-person study, 67 out of 100 on Effexor. In the ten-drug ranking, Effexor sits second and Cymbalta sits eighth, which means Cymbalta carries less of this effect, and still carries a good deal of it.

And the asking matters. When people are asked directly, they report the problem far more often than they volunteer it, which is why so many people sit quietly on it for years, convinced the fault is theirs. The drug flattens wanting, the condition under it flattens wanting, and a tired, pain-ridden or anxious life flattens wanting, and all three run at once.

None of that is a verdict on you. If what you want is to want it again, that is a fair wish, and it is reachable. The levers above are real, the prescriber conversation is real, and feeling like roommates is a state, and states change. You can feel normal again. You are not broken, and you do not have to solve this alone.

Keep reading

• SSRIs and the libido drop: what helps
• Does Wellbutrin affect sex drive?
• Chronic pain and low sex drive
• Depression and low libido
• Low libido in women
• Why is my libido so low?

Frequently asked questions

Does Cymbalta lower sex drive?
Yes. In a pooled analysis of four clinical trials by Nelson and colleagues (2006), 46.4% of the 736 people on duloxetine reported treatment-emergent sexual dysfunction, which was significantly more common than on placebo and significantly lower than paroxetine at 61.4% (p = .015). In a ten-drug ranking built from trials that asked directly, duloxetine sits eighth, so the effect is real, smaller than most of the class, and still well above placebo.

Does Effexor lower sex drive?
Yes, and it sits near the top of the rankings. In Montejo and colleagues' (2001) study of 1,022 outpatients, 67.3% of people on venlafaxine reported a sexual problem. In the ten-drug ranking from Serretti and Chiesa's (2009) meta-analysis, venlafaxine ranks second of ten. A cross-sectional survey of primary-care patients also placed venlafaxine XR in the 36% to 43% band for reporting a problem, so the effect is large and consistent across study designs.

Is Cymbalta better than an SSRI for sex drive?
In the head-to-head pooled trials, yes: duloxetine ran lower than paroxetine at 46.4% versus 61.4% (p = .015), and both ran above placebo. A 2014 network meta-analysis compared second-generation antidepressants across more than 26,000 people, but its credible intervals were wide and the overall evidence was rated low, so those wider comparisons are imprecise. In the ten-drug ranking, duloxetine sits eighth, below most SSRIs. Choose the drug with your prescriber, based on the condition it is prescribed for.

Do the sexual side effects of Cymbalta go away?
The best available data comes from an SSRI study, so read it as a pointer for an SNRI. Landen and colleagues (2005) found 41% of people reported the problem when asked directly versus 6% who volunteered it, and the rate did not fade over the treatment period, and the authors concluded these side effects do not abate with time. That study did not measure what happens after stopping, so that question stays open. Do not stop or change your medication without your doctor.

Can I take a botanical supplement with Cymbalta or Effexor?
Ask your prescriber first and bring the bottle. The label carries a caution: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients, which are conditions a prescriber already watches on these drugs. NUUD does nothing for the side effects of duloxetine, venlafaxine or any antidepressant, or for the conditions the drugs target, and there are no interaction studies for this formula, so your prescriber makes the call.

References

1. Nelson JC, Lu Pritchett Y, Martynov O, Yu JY, Mallinckrodt CH, Detke MJ. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Primary care companion to the Journal of clinical psychiatry. 2006;8(4):212-9. https://pubmed.ncbi.nlm.nih.gov/16964316/
2. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The Journal of clinical psychiatry. 2001;62 Suppl 3:10-21. https://pubmed.ncbi.nlm.nih.gov/11229449/
3. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of clinical psychopharmacology. 2009;29(3):259-66. https://pubmed.ncbi.nlm.nih.gov/19440080/
4. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. The Journal of clinical psychiatry. 2002;63(4):357-66. https://pubmed.ncbi.nlm.nih.gov/12000211/
5. Reichenpfader U, Gartlehner G, Morgan LC, et al. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug safety. 2014;37(1):19-31. https://pubmed.ncbi.nlm.nih.gov/24338044/
6. Kearns B, Cooper K, Orr M, Essat M, Hamilton J, Cantrell A. The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. Neuropsychiatric disease and treatment. 2022;18:1133-1143. https://pubmed.ncbi.nlm.nih.gov/35698594/
7. Welsch P, Uceyler N, Klose P, Walitt B, Hauser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. The Cochrane database of systematic reviews. 2018;2(2):CD010292. https://pubmed.ncbi.nlm.nih.gov/29489029/
8. Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. The Journal of clinical psychiatry. 2005;66(1):100-6. https://pubmed.ncbi.nlm.nih.gov/15669895/
9. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. The Cochrane database of systematic reviews. 2013;2013(5):CD003382. https://pubmed.ncbi.nlm.nih.gov/23728643/
10. de Aquino ACQ, Sarmento ACA, Teixeira RLA, et al. Pharmacological treatment of antidepressant-induced sexual dysfunction in women: A systematic review and meta-analysis of randomized clinical trials. Clinics (Sao Paulo, Brazil). 2025;80:100602. https://pubmed.ncbi.nlm.nih.gov/39985829/
11. Luft MJ, Dobson ET, Levine A, Croarkin PE, Strawn JR. Pharmacologic interventions for antidepressant-induced sexual dysfunction: a systematic review and network meta-analysis of trials using the Arizona sexual experience scale. CNS spectrums. 2021:1-10. https://pubmed.ncbi.nlm.nih.gov/33843553/

This article is for general education and is not medical advice. Depression, anxiety, fibromyalgia and nerve pain are medical conditions that only a licensed clinician can diagnose and manage, and Cymbalta (duloxetine) and Effexor (venlafaxine) are prescription medicines. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing any of those conditions, the side effects of any medication, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor before starting any new supplement, and do not stop or change your medication without your doctor.